Skip to content

Understanding the health effect of a bioactive peptide from egg: A pilot study

Diabetes | Prediabetes | Nutrition

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is a short tripeptide IRW (made of three amino acids). This is a feasibility study designed to assess the acute effect of IRW for the management of high sugar and blood pressure.

Participants will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing a protein powder. Each treatment will be separated by a minimum of 1-week.
Participants in the healthy control group will undergo 1 treatment only (one day).

null

Participation Requirements

  • Sex:

    Female, Male

  • Eligible Ages:

    18 to 70

Participation Criteria

Inclusion Criteria:
Female or male participants aged 18-70 years old.
Living in Edmonton (or Edmonton area/driving distance)

Group at risk of diabetes/having type 2 diabetes: with overweight or obesity and high glucose levels.

Participants with normal weight and normal glucose levels will be eligible for participation.
Exclusion Criteria:
Individuals with a previous history of cardiovascular disease, renal disorder, monogenic dyslipidemia, with endocrine disorders other than type 2 diabetes.
Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines and omega-3 supplements).
Pregnant/lactating women.
Individuals who regularly smoke.
Individuals with specific nutritional restrictions (e.g. vegetarianism excluding egg from their diet, vegan or with egg allergy).
Individuals who drink more than 2 alcoholic drinks per day.
Individuals with anemia

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Paulina Blanco Cervantes

[email protected]
780-492-9506
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00125956